2021
Chapter 10 Phosphatonins
Tebben P, Kumar R. Chapter 10 Phosphatonins. 2021, 215-233. DOI: 10.1016/b978-0-12-813073-5.00010-1.ChaptersSecreted frizzled-related protein 4X-linked hypophosphatemic ricketsPhosphorus balanceCell membrane integrityTumor-induced osteomalaciaFrizzled-related protein 4Fibroblast growth factor 23Matrix extracellular phosphoglycoproteinPhosphate homeostasisRenal phosphate reabsorptionPhosphate absorptionAbnormal phosphate homeostasisIntestinal phosphate absorptionMembrane integrityPhosphorusFibroblast growth factor 7Parathyroid hormonePhosphaturic peptidesHypophosphatemic ricketsPhosphate reabsorptionVitamin DRenal reabsorptionHypophosphatemic disordersNovel treatmentTumoral calcinosis
2018
Phosphaturic mesenchymal tumors: what an endocrinologist should know
Boland J, Tebben P, Folpe A. Phosphaturic mesenchymal tumors: what an endocrinologist should know. Journal Of Endocrinological Investigation 2018, 41: 1173-1184. PMID: 29446010, DOI: 10.1007/s40618-018-0849-5.Peer-Reviewed Original ResearchConceptsTumor-induced osteomalaciaPhosphaturic mesenchymal tumorMesenchymal tumorsCase of tumor-induced osteomalaciaRare cause of osteomalaciaPhosphaturic hormone fibroblast growth factor 23Recurrent genetic eventsHormone fibroblast growth factor 23Renal phosphate wastingFibroblast growth factor 23Autocrine/paracrine signaling loopTubular phosphate reabsorptionProgressive muscle weaknessProximal tubular phosphate reabsorptionConstellation of symptomsMolecular genetic aspectsBone painCalcitriol therapyCurative surgeryOncogenic osteomalaciaOffending tumorRare causeSurgical removalClinical featuresPrimary treatment
2017
Iron Replacement as A Therapeutic Approach For Renal Phosphate Wasting With Associated Iron Deficiency
Kumar A, Wermers R, Tebben P. Iron Replacement as A Therapeutic Approach For Renal Phosphate Wasting With Associated Iron Deficiency. AACE Clinical Case Reports 2017, 3: e260-e263. DOI: 10.4158/ep161330.cr.Peer-Reviewed Case Reports and Technical NotesAutosomal dominant hypophosphatemic ricketsTumor-induced osteomalaciaRenal phosphate wastingIron replacementIron deficiencyPhosphate wastingHypophosphatemic ricketsClinical improvementWeeks of iron therapyAutosomal recessive hypophosphatemic ricketsProgressive clinical improvementX-linked hypophosphatemic ricketsFibroblast growth factor 23Worsening muscle weaknessPotential treatment optionCalcitriol therapyHypophosphatemic osteomalaciaIron therapyDiffuse painFractional excretionTreatment optionsElevated FGF23Family historyProgressive weaknessFibroblast growth factor
2013
Chapter 16 Phosphatonins
Tebben P, Berndt T, Kumar R. Chapter 16 Phosphatonins. 2013, 373-390. DOI: 10.1016/b978-0-12-415853-5.00016-9.ChaptersMatrix extracellular phosphoglycoproteinSecreted frizzled-related protein 4Skeletal mineralizationAssociated with abnormal mineralizationActive vitamin D metaboliteFrizzled-related protein 4Fibroblast growth factor 23Vitamin D metabolitesRenal phosphate reabsorptionIntestinal phosphate absorptionPhosphaturic peptidesParathyroid hormoneD metabolitesChronic hypophosphatemiaPhosphate reabsorptionAbnormal mineralizationProtein 4Phosphorus homeostasisPhosphate homeostasisBone mineralizationEnergy homeostasisCell membrane integrityFGF23Phosphate absorption
2012
Vitamin D and the kidney
Kumar R, Tebben P, Thompson J. Vitamin D and the kidney. Archives Of Biochemistry And Biophysics 2012, 523: 77-86. PMID: 22426203, PMCID: PMC3361542, DOI: 10.1016/j.abb.2012.03.003.Peer-Reviewed Original Research
2005
Elevated fibroblast growth factor 23 in women with malignant ovarian tumors.
Tebben P, Kalli K, Cliby W, Hartmann L, Grande J, Singh R, Kumar R. Elevated fibroblast growth factor 23 in women with malignant ovarian tumors. Mayo Clinic Proceedings 2005, 80: 745-51. PMID: 15948297, DOI: 10.1016/s0025-6196(11)61528-0.Peer-Reviewed Original ResearchConceptsAdvanced-stage ovarian cancerEarly-stage ovarian cancerOvarian cancerFGF23 concentrationsPlasma FGF23 concentrationCFGF23 concentrationsSerum iFGF23Ovarian tumorsHealthy womenMalignant ovarian cancer cellsMalignant ovarian tumorsBenign ovarian tumorsAdvanced-stage diseaseAdvanced-stage tumorsFibroblast growth factor 23Elevated fibroblast growth factorOvarian cancer cellsSerum phosphate concentrationStage of diseaseSerum FGF23 concentrationsOvarian massBenign diseaseSerum phosphorusBenign massesMayo ClinicElevated Fibroblast Growth Factor 23 in Women With Malignant Ovarian Tumors
Tebben P, Kalli K, Cliby W, Hartmann L, Grande J, Singh R, Kumar R. Elevated Fibroblast Growth Factor 23 in Women With Malignant Ovarian Tumors. Mayo Clinic Proceedings 2005, 80: 745-751. DOI: 10.4065/80.6.745.Peer-Reviewed Original ResearchAdvanced-stage ovarian cancerEarly-stage ovarian cancerOvarian cancerFibroblast growth factor 23FGF23 concentrationsPlasma FGF23 concentrationCFGF23 concentrationsSerum iFGF23Ovarian tumorsHealthy womenAdvanced-stage epithelial ovarian cancerMalignant ovarian cancer cellsElevated fibroblast growth factor 23Benign ovarian tumorsMalignant ovarian tumorsAdvanced-stage diseaseEpithelial ovarian cancerAdvanced-stage tumorsOvarian cancer cellsStage of diseaseSerum phosphate concentrationSerum FGF23 concentrationsOvarian massBenign diseaseSerum phosphorus
2004
Fibroblast Growth Factor 23, Parathyroid Hormone, and 1α,25-Dihydroxyvitamin D in Surgically Treated Primary Hyperparathyroidism
Tebben P, Singh R, Clarke B, Kumar R. Fibroblast Growth Factor 23, Parathyroid Hormone, and 1α,25-Dihydroxyvitamin D in Surgically Treated Primary Hyperparathyroidism. Mayo Clinic Proceedings 2004, 79: 1508-1513. PMID: 15595334, DOI: 10.4065/79.12.1508.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkersDihydroxycholecalciferolsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsFollow-Up StudiesHumansHyperparathyroidismMaleMiddle AgedParathyroid GlandsParathyroid HormoneParathyroidectomyPostoperative CarePreoperative CareProbabilityProspective StudiesSampling StudiesSensitivity and SpecificitySeverity of Illness IndexStatistics, NonparametricTreatment OutcomeConceptsBone-specific alkaline phosphataseBone-specific alkaline phosphatase concentrationsFibroblast growth factor 23Primary hyperparathyroidismParathyroid hormoneSerum phosphorus concentrationFGF23 concentrationsSerum calciumSurgically treated primary hyperparathyroidismElevated serum calciumLow-normal rangeParathyroid hormone concentrationsAdult patientsPreoperative stateSerum phosphorusPostoperative stateHyperparathyroidismHealthy controlsFibroblast growth factorPatientsFGF23Growth factorSurgerySerumPhosphorus homeostasis